Company news

Dare Bioscience, Inc. news in 2019

Dare Bioscience, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study

December 17, 2019

Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

December 10, 2019

Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems

December 9, 2019

Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

November 20, 2019

Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update

November 13, 2019

Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate

November 11, 2019

Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform

November 10, 2019

Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360

October 30, 2019

Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference

October 27, 2019

Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society for Reproductive Medicine 2019 Scientific Congress & Expo

October 9, 2019

Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Pharmaceutics

September 10, 2019

Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder

September 8, 2019

Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock

April 8, 2019

Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock

April 7, 2019

Decks in 2019